Last reviewed · How we verify
celecoxib and chemotherapy
At a glance
| Generic name | celecoxib and chemotherapy |
|---|---|
| Sponsor | Organisation for Oncology and Translational Research |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy (PHASE2)
- Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors (PHASE2)
- Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation (EARLY_PHASE1)
- Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors (PHASE2)
- Intravenous Lidocaine Plus Port-Site Ropivacaine for Recovery After Laparoscopic Surgery (PHASE3)
- Multimodal Exercise Therapy for Non-Surgical Intervention of Nonspecific Low Back Pain. (NA)
- Efficacy and Safety of Intravenous Dexamethasone Palmitate Treatments in Acute and Subacute Herpes Zoster Pain (NA)
- The Seven Trial: Exploiting the Unfolded Protein Response (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: